Skip to main content

View full-text article in PMC

. 2019 May 25;70(8):1591–1595. doi: 10.1093/cid/ciz444

Table 2.

Prevalence of Scabies and Impetigo at Baseline, 12, and 36 Months

	Prevalence at Baseline(95% CI)n/N	Prevalence at 12 Months(95% CI) n/N	Prevalence at 36 Months(95% CI)n/N	Absolute Reduction in Prevalence at 12 Months^a(95% CI)	Relative Reduction in Prevalence at 12 Months^a(95% CI)	Absolute Reduction in Prevalence at 36 Months^a(95% CI)	Relative Reduction in Prevalence at 36 Months^a(95% CI)	Absolute Change in Prevalence Between 12 and 36 Months(95% CI)
Scabies	18.7% (16.6 to 20.8) (261/1399)	2.3% (1.6 to 3.3) (29/1261)	4.7% (3.6 to 6.1) (57/1210)	16.6% (14.5 to 18.8)	89% (77.5 to 100)	14.0% (11.5 to 16.4)	74.9% (61.5 to 87.7)	+2.4% (+0.1 to + 3.9)
Impetigo	24.8% (22.6 to 27.2) (347/1399)	6.4% (5.2 to 8.0) (81/1261)	9.6% (8.1 to 11.4) (116/1210)	18.7% (16.2 to 21.3)	75% (65.2 to 85.7)	15.2% (9.6 to 24.8)	61.3% (38.7 to 100)	+3.2% (+0.9 to +6.4)

Abbreviation: CI, confidence interval.

^aCompared to baseline prevalence.